Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL517921 | 0.88 | DHODH (0.53) | DHODHNR4A2 | |
| SCHEMBL299934 | 0.88 | DHODH (0.55) | DHODHNR4A2 | |
| SCHEMBL517795 | 0.85 | DHODH (0.43) | DHODH | |
| SCHEMBL4399442 | 0.85 | DHODH (0.43) | DHODH | |
| SCHEMBL517020 | 0.81 | DHODH (0.58) | DHODH | |
| SCHEMBL3914869 | 0.76 | DHODH (0.36) | DHODHNR4A2 | |
| SCHEMBL517414 | 0.74 | DHODH (0.53) | DHODHNR4A2 | |
| SCHEMBL249081 | 0.71 | DHODH (1.00) | DHODHNR4A2 | |
| SCHEMBL3917145 | 0.70 | DHODH (1.00) | DHODHNR4A2 | |
| SCHEMBL517489 | 0.70 | DHODH (1.00) | DHODHNR4A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8354433-B2 | Anti-inflammatory agents as virostatic compounds | 4SC AG (DE) | 2013-01-15 | — | — | US | claimed |
| EP-2427186-B1 | DIHYDROOROTATE-DEHYDROGENASEE INHIBITORS AS VIROSTATIC COMPOUNDS | PANOPTES PHARMA GES M B H (AT) | 2022-01-12 | — | — | EP | disclosed |
| US-9795590-B2 | Anti-inflammatory agents as virostatic compounds | PANOPTES PHARMA GMBH (AT) | 2017-10-24 | — | — | US | disclosed |
| US-20170027905-A1 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | Panoptes Hparma GmbH (AT) | 2017-02-02 | — | — | US | disclosed |
| US-8354433-B2 | Anti-inflammatory agents as virostatic compounds | 4SC AG (DE) | 2013-01-15 | — | — | US | disclosed |
| US-20120028985-A1 | COMBINATIONAL THERAPY FOR TREATING AUTOIMMUNE DISEASE | 4SC AG (DE) | 2012-02-02 | — | — | US | disclosed |
| EP-2362771-A1 | COMBINATIONAL THERAPY COMPRISING DHODH INHIBITOR AND METHOTREXATE FOR TREATING AUTOIMMUNE DISEASE | 4SC AG (DE) | 2011-09-07 | — | — | EP | disclosed |
| US-20100280081-A1 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | 4SC AG (DE) | 2010-11-04 | — | — | US | disclosed |
| WO-2010052027-A1 | COMBINATIONAL THERAPY COMPRISING DHODH INHIBITOR AND METHOTREXATE FOR TREATING AUTOIMMUNE DISEASE | 4SC AG (DE) | 2010-05-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028985-A1 | COMBINATIONAL THERAPY FOR TREATING AUTOIMMUNE DISEASE | HLA-DRB1, IL2, SSB | DHODH 2305/4885NR4A2 2709/4885 |
| US-20170027905-A1 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | TNF, RPL35, NFKBIA | DHODH 2832/4885NR4A2 3102/4885 |
| US-20100280081-A1 | ANTI-INFLAMMATORY AGENTS AS VIROSTATIC COMPOUNDS | TNF, MIF, IL1B | DHODH 2796/4885NR4A2 2483/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.